Table 2.
Treatment assignment and response assessment, B cell ALL (n = 196)
| Variable | Value | Count | % |
|---|---|---|---|
| Induction arma | A | 125 | 63.8 |
| B | 50 | 25.5 | |
| C | 21 | 10.7 | |
| Day 15 BM morphology | M1 | 182 | 92.9 |
| M2 | 8 | 4.1 | |
| M3 | 5 | 2.6 | |
| Missing | 1 | 0.5 | |
| Day 15 BM MRD (%) | < 0.01 | 84 | 42.9 |
| ≥ 0.01 | 50 | 25.5 | |
| Not available | 62 | 31.6 | |
| Day 29 BM morphology | M1 | 191 | 97.4 |
| M2 | 1 | 0.5 | |
| M3 | 2 | 1.0 | |
| Not available | 2 | 1.0 | |
| Day 29 BM MRD (%) | < 0.01 (negative) | 177 | 90.3 |
| ≥ 0.01 (positive) | 13 | 6.6 | |
| Not determined | 6 | 3.1 | |
| Post induction armb | A | 114 | 58.2 |
| B | 38 | 19.4 | |
| C | 40 | 20.4 | |
| Not applicable | 4 | 2.0 |
aPatients with Philadelphia translocation positive were excluded from the analysis (n = 4)
b4 patients were not eligible for post-induction analysis and were reported as “Not applicable”. Post-induction Arms C and C + HDMTX were combined